406 related articles for article (PubMed ID: 31426807)
1. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
[TBL] [Abstract][Full Text] [Related]
2. pH-Responsive PEG-Shedding and Targeting Peptide-Modified Nanoparticles for Dual-Delivery of Irinotecan and microRNA to Enhance Tumor-Specific Therapy.
Juang V; Chang CH; Wang CS; Wang HE; Lo YL
Small; 2019 Dec; 15(49):e1903296. PubMed ID: 31709707
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation.
Wang J; Su G; Yin X; Luo J; Gu R; Wang S; Feng J; Chen B
Biomed Pharmacother; 2019 Dec; 120():109493. PubMed ID: 31586902
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
5. PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer.
Yang Y; Huang Z; Li J; Mo Z; Huang Y; Ma C; Wang W; Pan X; Wu C
Adv Healthc Mater; 2019 Dec; 8(23):e1900965. PubMed ID: 31664795
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
[TBL] [Abstract][Full Text] [Related]
7. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
[No Abstract] [Full Text] [Related]
8. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
[TBL] [Abstract][Full Text] [Related]
10. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
11. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi H; Cho BC; Michel MC; Solca F
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
[TBL] [Abstract][Full Text] [Related]
14. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
15. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
Lo YL; Lin HC; Tseng WH
Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
[TBL] [Abstract][Full Text] [Related]
16. Photo-induced specific intracellular release EGFR inhibitor from enzyme/ROS-dual sensitive nano-platforms for molecular targeted-photodynamic combinational therapy of non-small cell lung cancer.
Zhang M; Zhang X; Cai S; Mei H; He Y; Huang D; Shi W; Li S; Cao J; He B
J Mater Chem B; 2020 Sep; 8(35):7931-7940. PubMed ID: 32779670
[TBL] [Abstract][Full Text] [Related]
17. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.
Guan SS; Chang J; Cheng CC; Luo TY; Ho AS; Wang CC; Wu CT; Liu SH
Oncotarget; 2014 Jul; 5(13):4868-80. PubMed ID: 24947902
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer.
Ma W; Liu B; Li J; Jiang J; Zhou R; Huang L; Li X; He X; Zhou Q
Biomed Pharmacother; 2018 Sep; 105():670-676. PubMed ID: 29906744
[TBL] [Abstract][Full Text] [Related]
19. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
20. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
